Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (111-120 of 336) with videos related to

Pageof 34
Sort By:
Bladder (San Francisco, Calif.)|February 13, 2025
Molecular classification using Lund University algorithm and clinical correlations in muscle-invasive bladder cancer: Insights from a retrospective studyDavide Campobasso, Simone Vezzini, Sebastiano Buti, et al.
Tumori|August 8, 2007
A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancerMatteo Dalla Chiesa, Sebastiano Buti, Gianluca Tomasello, et al.
Future Oncology (London, England)|June 18, 2016
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancerSebastiano Buti, Chiara Ciccarese, Roberto Iacovelli, et al.
Acta Bio-Medica : Atenei Parmensis|March 12, 2008
Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trialMatteo Dalla Chiesa, Rodolfo Passalacqua, Maria Michiara, et al.
Cancer Treatment Reviews|February 2, 2016
AR-V7 and prostate cancer: The watershed for treatment selection?Chiara Ciccarese, Matteo Santoni, Matteo Brunelli, et al.
Critical Reviews in Oncology/Hematology|March 2, 2026
When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinomaSebastiano Buti, Betty Dalla Valle, Alessandro Acunzo, et al.
Scientific Reports|September 15, 2019
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patientsSebastiano Buti, Pierre I Karakiewicz, Melissa Bersanelli, et al.
Expert Review of Anticancer Therapy|February 11, 2025
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated reviewGiulia Claire Giudice, Michele Maffezzoli, Irene Testi, et al.
Cancers|January 21, 2023
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic ConsequencesMatteo Santoni, Javier Molina-Cerrillo, Giorgio Santoni, et al.
Oncology Research|April 7, 2025
The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative reviewMichele Maffezzoli, Giulia Claire Giudice, Giacomo Iovane, et al.
Pageof 34

Showing results (111-120 of 336) with videos related to

Sort By:
Pageof 34
Bladder (San Francisco, Calif.)|February 13, 2025
Molecular classification using Lund University algorithm and clinical correlations in muscle-invasive bladder cancer: Insights from a retrospective studyDavide Campobasso, Simone Vezzini, Sebastiano Buti, et al.
Tumori|August 8, 2007
A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancerMatteo Dalla Chiesa, Sebastiano Buti, Gianluca Tomasello, et al.
Future Oncology (London, England)|June 18, 2016
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancerSebastiano Buti, Chiara Ciccarese, Roberto Iacovelli, et al.
Acta Bio-Medica : Atenei Parmensis|March 12, 2008
Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trialMatteo Dalla Chiesa, Rodolfo Passalacqua, Maria Michiara, et al.
Cancer Treatment Reviews|February 2, 2016
AR-V7 and prostate cancer: The watershed for treatment selection?Chiara Ciccarese, Matteo Santoni, Matteo Brunelli, et al.
Critical Reviews in Oncology/Hematology|March 2, 2026
When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinomaSebastiano Buti, Betty Dalla Valle, Alessandro Acunzo, et al.
Scientific Reports|September 15, 2019
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patientsSebastiano Buti, Pierre I Karakiewicz, Melissa Bersanelli, et al.
Expert Review of Anticancer Therapy|February 11, 2025
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated reviewGiulia Claire Giudice, Michele Maffezzoli, Irene Testi, et al.
Cancers|January 21, 2023
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic ConsequencesMatteo Santoni, Javier Molina-Cerrillo, Giorgio Santoni, et al.
Oncology Research|April 7, 2025
The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative reviewMichele Maffezzoli, Giulia Claire Giudice, Giacomo Iovane, et al.
Pageof 34